Samantha L. Grimley

Melbourne, VIC 3000, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Common Acquisition of Broadly Neutralizing Antibodies in an HTLV-1c+ First Nations Cohort from Central Australia.

Common Acquisition of Broadly Neutralizing Antibodies in an HTLV-1c+ First Nations Cohort from Central Australia.

Journal: Viruses
Published: February 25, 2026

Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59.

Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59.

Journal: NPJ vaccines
Published: July 04, 2025

Polarized Calu-3 Cells Serve as an Intermediary Model for SARS-CoV-2 Infection.

Polarized Calu-3 Cells Serve as an Intermediary Model for SARS-CoV-2 Infection.

Journal: Methods in molecular biology (Clifton, N.J.)
Published: January 17, 2025

mRNA vaccines encoding membrane-anchored RBDs of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprinting.

mRNA vaccines encoding membrane-anchored RBDs of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprinting.

Journal: Molecular therapy. Methods & clinical development
Published: October 30, 2023

SARS-CoV-2 mouse adaptation selects virulence mutations that cause TNF-driven age-dependent severe disease with human correlates.

SARS-CoV-2 mouse adaptation selects virulence mutations that cause TNF-driven age-dependent severe disease with human correlates.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 31, 2023

Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster.

Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster.

Journal: EBioMedicine
Published: July 17, 2023

Uncovering strain- and age-dependent innate immune responses to SARS-CoV-2 infection in air-liquid-interface cultured nasal epithelia.

Uncovering strain- and age-dependent innate immune responses to SARS-CoV-2 infection in air-liquid-interface cultured nasal epithelia.

Journal: iScience
Published: May 19, 2023

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.

Journal: EBioMedicine
Published: September 15, 2022

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2.

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2.

Journal: iScience
Published: March 24, 2022

Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection.

Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection.

Journal: International journal of molecular sciences
Published: December 22, 2021

Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody.

Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody.

Journal: Cell reports. Medicine
Published: October 21, 2021

A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.

A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.

Journal: EBioMedicine
Published: July 20, 2021
Showing 1-12 of 17

Last Updated: 09/26/2026